Quickstart Highlights
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors[1], studied for substantial weight loss and metabolic improvement in obesity and type 2 diabetes[2][3]. With an extended half-life of approximately 6 days, this peptide enables convenient once-weekly subcutaneous dosing with a gradual titration protocol to optimize tolerability[1][4].
- Reconstitute: Add 1.2 mL bacteriostatic water → 5 mg/mL concentration for precise weekly dosing.
- Typical weekly range: 2–12 mg once weekly (gradual escalation over 12+ weeks).
- Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 0.05 mg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Important: Before viewing any protocol, please consult our Prep & Injection Guide for essential preparation and safety instructions.Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing
Standard / Gradual Titration Approach (1.2 mL = 5 mg/mL)
- Reconstitute: Add 1.2 mL bacteriostatic water → 5 mg/mL concentration.
- Typical weekly range: 2–12 mg once weekly (gradual escalation over 12+ weeks).
- Easy measuring: At 5 mg/mL, 1 mg = 0.20 mL = 20 units on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Standard / Gradual Titration Approach (1.2 mL = 5 mg/mL)
| Week(s) | Weekly Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2 mg | 40 units (0.40 mL) |
| Weeks 5–8 | 4 mg | 80 units (0.80 mL) |
| Weeks 9–12 | 8 mg | 160 units (1.60 mL) |
| Weeks 13+ | 12 mg | 240 units (2.40 mL) |
Frequency: Inject once weekly subcutaneously. This schedule follows clinical trial protocols that demonstrated significant weight loss (up to 24% at 48 weeks with 12 mg weekly)[2] while minimizing gastrointestinal adverse events through gradual escalation[1][4]. Starting at 2 mg weekly (versus 4 mg) significantly reduces initial GI side effects. Higher weekly doses require multiple vials or split injections across different sites.
Reconstitution Steps
- Draw 1.2 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Since this vial contains 6 mg and is reconstituted with 1.2 mL, higher weekly doses (8–12 mg) will naturally require multiple vials.
Lower doses (2–4 mg) remain well within practical syringe volumes.
Supplies Needed
Plan based on a 12–48 week weekly protocol with gradual titration to maintenance dose.
- Peptide Vials (Retatrutide, 6 mg each):
Requirements increase with dose escalation.
- 12 weeks (2 → 4 → 8 mg titration): ~13 vials
- 24 weeks (up to 12 mg weekly): ~40 vials
- 48 weeks (maintenance at 12 mg): ~115 vials
- Insulin Syringes (U-100, 1 mL):
- Per week: 1 syringe (once-weekly dosing)
- 12 weeks: 12 syringes
- 24 weeks: 24 syringes
- 48 weeks: 48 syringes
- Bacteriostatic Water (10 mL bottles):
Use 1.2 mL per vial for reconstitution.
- 12 weeks (13 vials): 15.6 mL → 2 × 10 mL bottles
- 24 weeks (40 vials): 48 mL → 5 × 10 mL bottles
- 48 weeks (115 vials): 138 mL → 14 × 10 mL bottles
- Alcohol Swabs:
One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 12 weeks: 24 swabs → 1 × 100-count box
- 24 weeks: 48 swabs → 1 × 100-count box
- 48 weeks: 96 swabs → 1 × 100-count box
![Peptide Vial](http://www.dosagepeptide.com/wp-content/uploads/2025/12/Retatrutide-6mg001.png" alt="Retatrutide (6mg Vial)" /></div>)
Protocol Overview
Concise summary of the once-weekly regimen based on clinical trial protocols.
- Goal: Achieve substantial weight loss (up to ~24% of body weight) and improved metabolic markers through triple-receptor agonism[2][5].
- Schedule: Weekly subcutaneous injections for 12+ weeks with gradual dose escalation.
- Dose Range: 2–12 mg once weekly; clinical trials evaluated up to 12 mg as the maximum maintenance dose[1][3].
- Reconstitution: Add 1.2 mL bacteriostatic water per 6 mg vial → yields a 5 mg/mL concentration (ideal for accurate titration from 2–12 mg).
- Storage: Lyophilized vial frozen at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Dosing Protocol
Evidence-based weekly titration approach from clinical trials.
- Start: 2 mg once weekly for the first 4 weeks to establish tolerability[1][4].
- Escalation: Increase to 4 mg weekly (Weeks 5–8), then 8 mg weekly (Weeks 9–12)[1].
- Maintenance: 12 mg weekly from Week 13 onward for maximal efficacy; 8 mg weekly remains a validated alternative maintenance dose[2].
- Frequency: Once weekly (subcutaneous). Using the same day/time each week improves consistency.
- Cycle Length: Minimum 12 weeks for escalation; clinical trials extended protocols to 48 weeks with sustained, progressive weight loss[2].
- Timing: Any consistent weekly schedule is acceptable; rotate injection sites at each dose.
Storage Instructions
Proper storage maintains peptide stability and potency.
- Lyophilized: Store at −20 °C (−4 °F) or colder for long-term preservation; protect from moisture and light[11][12].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing. Use within 2–4 weeks for maximum stability and potency[11].
- Handling: Allow frozen lyophilized vials to reach room temperature before opening to avoid condensation. Do not expose reconstituted solution to heat or direct sunlight.
- Aliquoting: For storage beyond 4 weeks, unused portions may be aliquoted and frozen. Avoid repeated freeze–thaw cycles to prevent degradation[12].
Important Notes
Practical considerations for safe and effective weekly administration.
- Weekly consistency: Choose a specific day and time for your injection each week and maintain this schedule throughout the protocol.
- Gradual titration is essential: Starting at 2 mg weekly (rather than higher doses) significantly reduces the risk of early gastrointestinal side effects[4].
- Syringe use: Always use a new sterile U-100 insulin syringe for every injection, and dispose of it immediately in a puncture-proof sharps container[14].
- Injection site rotation: Rotate sites weekly (abdomen, thighs, upper arms), spacing each injection at least 1 inch apart to reduce irritation and prevent lipohypertrophy[15].
- Large volumes: For doses requiring more than 1.0 mL (>100 units), split the injection into multiple sites or use multiple reconstituted vials as needed.
- Side-effect monitoring: Mild nausea or gastrointestinal discomfort is common during escalation. If symptoms become significant, extend the time at your current dose before increasing.
How This Works
Retatrutide is a first-in-class triple agonist that simultaneously activates three key metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor[1][5]. This triple-receptor mechanism produces synergistic effects on appetite suppression, metabolic rate, and glucose regulation that surpass single or dual agonists.
The GLP-1 pathway reduces appetite and slows gastric emptying; GIP enhances insulin secretion and may support lipid metabolism; and glucagon receptor activation increases energy expenditure and promotes fat oxidation[5][8]. Combined, these effects create profound metabolic improvements.
Retatrutide has an extended half-life of ~6 days, allowing convenient once-weekly dosing while maintaining steady therapeutic levels[1].
In clinical trials, participants receiving 12 mg weekly achieved an average of 24% body-weight reduction over 48 weeks[2]. In adults with type 2 diabetes, weekly doses up to 12 mg produced approximately 17% weight loss at 36 weeks, along with ~2.0% reductions in HbA1c compared to placebo[3].
A 2025 meta-analysis of three trials (878 participants) confirmed retatrutide leads to significantly greater weight reduction than placebo — averaging ~14% total body-weight loss — with no significant increase in overall adverse events[6][7].
Lifestyle Factors
Complementary strategies to optimize outcomes during retatrutide protocols.
- Nutrition: Adopt a balanced, protein-forward diet (1.0–1.2 g/kg body weight) to preserve lean mass during weight loss[10].
- Hydration: Maintain adequate fluid intake, especially during dose titration when GI effects are most common.
- Physical activity: Combine resistance training (2–3×/week) with moderate aerobic exercise to support metabolic adaptations and preserve muscle mass.
- Sleep & stress: Prioritize 7–9 hours of quality sleep and implement stress management techniques to support hormonal balance and adherence.
- Meal timing: Some individuals find smaller, more frequent meals help manage GI side effects during initial titration.
Potential Benefits & Side Effects
Observations from phase 2 and phase 3 clinical trials in humans.
Potential Benefits
- Substantial weight loss: Up to 24% reduction in body weight at 48 weeks with 12 mg weekly dosing[2].
- Glycemic improvement: Significant HbA1c reductions (approximately 2.0%) in adults with type 2 diabetes[3].
- Metabolic benefits: Improvements in lipid profiles, blood pressure, and cardiovascular risk markers[1][5].
- Convenient dosing: Once-weekly subcutaneous administration improves adherence compared to daily regimens[1].
Common Side Effects
- Gastrointestinal effects: Nausea, diarrhea, vomiting, and constipation are the most common adverse events; typically mild-to-moderate and diminish over time[2][4].
- Starting at 2 mg weekly (versus 4 mg) significantly reduces initial GI adverse events[4].
- Injection site reactions: Mild redness, swelling, or discomfort at injection sites may occur; rotate sites to minimize.
- Overall safety profile: Meta-analysis found no significant increase in overall adverse events compared to placebo[6][7].
Injection Technique
Pre-Injection Preparation
- Wash hands thoroughly with soap and water[14].
- Clean the vial stopper with an alcohol swab and allow to air dry.
- Select injection site (abdomen, thigh, or upper arm) and clean with a fresh alcohol swab; allow to dry completely[13].
- Draw prescribed dose carefully; check for air bubbles and expel if present.
Injection Procedure
- Pinch a skinfold of approximately 1 inch between thumb and forefinger[15].
- Insert needle at a 90-degree angle (45-degree if subcutaneous fat layer is thin) into the pinched skin[13][14].
- Do not aspirate for subcutaneous injections (aspiration is not required and may increase discomfort)[13].
- Inject slowly and steadily; depress plunger completely.
- Withdraw needle straight out and apply gentle pressure with clean gauze if needed.
Post-Injection Care
- Dispose of used syringe immediately in a puncture-proof sharps container; never recap needles[14].
- Return reconstituted vial to refrigerator promptly.
- Rotate injection sites weekly (at least 1 inch apart) to prevent lipohypertrophy[15].
- Monitor for excessive redness, swelling, or signs of infection at injection site.
Recommended Source
We recommend Prime Lab Peptides for high-purity Retatrutide (5 mg vials).
Why Prime Lab Peptides?
- Third-party tested: Each batch includes Certificate of Analysis (COA) verifying purity and composition.
- Consistent quality: ISO-aligned manufacturing and handling standards ensure reliable product integrity.
- Cold-chain integrity: Temperature-controlled shipping and storage throughout fulfillment process.
- Research-grade purity: Suitable for educational and research applications requiring high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational compound; consult qualified healthcare professionals before considering any peptide protocol. This information is for research and educational purposes only.
References
-
New England Journal of Medicine (2023)
— Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2 trial; 48-week results) -
JAMA Network (2023)
— Retatrutide Phase 2 Obesity Trial: detailed efficacy and safety data (24% weight loss at 12 mg weekly) -
The Lancet (2023)
— Retatrutide in type 2 diabetes: Phase 2 trial (weight loss and glycemic outcomes at 36 weeks) -
PubMed / NEJM (2023)
— Retatrutide dosing and tolerability: starting at 2 mg vs 4 mg reduces GI adverse events -
Metabolites (PMC, 2025)
— Retatrutide—A Game Changer in Obesity Pharmacotherapy (comprehensive review of mechanism and trials) -
Baylor University Medical Center Proceedings (PMC, 2025)
— Efficacy and safety of retatrutide for obesity: meta-analysis of RCTs (878 participants) -
PubMed (2025)
— Meta-analysis: Retatrutide achieves ~14% greater weight reduction vs placebo with no increase in adverse events -
Molecular Metabolism (2025)
— Preclinical tri-agonist NN1706 (related compound): mechanism and pharmacokinetics -
Nature Reviews Endocrinology (2024)
— Triple agonist therapies for obesity and diabetes: clinical landscape review -
Journal of Cachexia, Sarcopenia and Muscle (PMC)
— Protein requirements during weight loss: preserving lean mass -
GenScript
— Peptide Storage and Handling Guidelines (technical bulletin for lyophilized and reconstituted peptides) -
Bachem
— Handling and Storage Guidelines for Peptides (technical article on stability and freeze-thaw cycles) -
Centers for Disease Control and Prevention (CDC)
— Vaccine Administration: Subcutaneous Injection (technique, angle, and site guidance) -
NCBI Bookshelf
— Injection Administration Best Practices (aseptic technique, sharps disposal, and safety) -
Pharmacologic Considerations of the Subcutaneous Route (PMC)
— Subcutaneous injection technique and site rotation to prevent lipohypertrophy -
Prime Lab Peptides
— Retatrutide (6 mg) product page (quality documentation and specifications)